Management of patients with diabetes and CKD : conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference

Show full item record



Permalink

http://hdl.handle.net/10138/172966

Citation

Perkovic , V , Agarwal , R , Fioretto , P , Hemmelgarn , B R , Levin , A , Thomas , M C , Wanner , C , Kasiske , B L , Wheeler , D C , Groop , P-H & Conf Participants 2016 , ' Management of patients with diabetes and CKD : conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference ' , Kidney International , vol. 90 , no. 6 , pp. 1175-1183 . https://doi.org/10.1016/j.kint.2016.09.010

Title: Management of patients with diabetes and CKD : conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference
Author: Perkovic, Vlado; Agarwal, Rajiv; Fioretto, Paola; Hemmelgarn, Brenda R.; Levin, Adeera; Thomas, Merlin C.; Wanner, Christoph; Kasiske, Bertram L.; Wheeler, David C.; Groop, Per-Henrik; Conf Participants
Contributor: University of Helsinki, Clinicum
Date: 2016-12
Language: eng
Number of pages: 9
Belongs to series: Kidney International
ISSN: 0085-2538
URI: http://hdl.handle.net/10138/172966
Abstract: The prevalence of diabetes around the world has reached epidemic proportions and is projected to increase to 642 million people by 2040. Diabetes is already the leading cause of end-stage kidney disease (ESKD) in most developed countries, and the growth in the number of people with ESKD around the world parallels the increase in diabetes. The presence of kidney disease is associated with a markedly elevated risk of cardiovascular disease and death in people with diabetes. Several new therapies and novel investigational agents targeting chronic kidney disease patients with diabetes are now under development. This conference was convened to assess our current state of knowledge regarding optimal glycemic control, current antidiabetic agents and their safety, and new therapies being developed to improve kidney function and cardiovascular outcomes for this vulnerable population.
Subject: antidiabetic agents
cardiovascular disease
chronic kidney disease
diabetes
glycemic control
renoprotection
STAGE RENAL-DISEASE
CONVERTING ENZYME-INHIBITION
DIETARY-SODIUM RESTRICTION
INTENSIVE GLUCOSE CONTROL
ALBUMIN EXCRETION RATE
BLOOD-PRESSURE
CARDIOVASCULAR OUTCOMES
RANDOMIZED-TRIAL
GLYCEMIC CONTROL
RECEPTOR ANTAGONIST
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0085253816305154_main.pdf 276.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record